about
Is arthropod saliva the achilles' heel of vector-borne diseases?Novel anti-filamin-A antibody detects a secreted variant of filamin-A in plasma from patients with breast carcinoma and high-grade astrocytoma.Myth, menace or medical blessing? The clinical potential and the problems of genetic vaccinesComparison of Plasmodium berghei challenge models for the evaluation of pre-erythrocytic malaria vaccines and their effect on perceived vaccine efficacy.Nucleic acid for the treatment of cancer: genetic vaccines and DNA adjuvants.Apoptosis is essential for the increased efficacy of alphaviral replicase-based DNA vaccines.Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathwaysType I Interferons are essential for the efficacy of replicase-based DNA vaccines.Pericyte-derived MFG-E8 regulates pathologic angiogenesisIdentification and targeting of tumor escape mechanisms: a new hope for cancer therapy?Danger, death and DNA vaccines.MDA-7/IL-24 is a unique cytokine--tumor suppressor in the IL-10 family.Is genetic vaccination against allergy possible?Complement 3d: from molecular adjuvant to target of immune escape mechanisms.Enhancement of DNA tumor vaccine efficacy by gene gun-mediated codelivery of threshold amounts of plasmid-encoded helper antigen.Murine epidermal Langerhans cells and langerin-expressing dermal dendritic cells are unrelated and exhibit distinct functionsRole of TLR3 in the immunogenicity of replicon plasmid-based vaccines.Immunization with a low-dose replicon DNA vaccine encoding Phl p 5 effectively prevents allergic sensitization.Inhibition of type I allergic responses with nanogram doses of replicon-based DNA vaccines.Genetic immunization with LYVE-1 cDNA yields function-blocking antibodies against native protein.Role of immune cell subsets in the establishment of vector-borne infections.Gene gun immunization to combat malaria.NIAID workshop on immunity to malaria: addressing immunological challenges.Immunological consequences of arthropod vector-derived salivary factors.Inhibitory effects of B cells on antitumor immunity.Improving DNA vaccines against malaria: could immunization by gene gun be the answer?C3d-defined complement receptor-binding peptide p28 conjugated to circumsporozoite protein provides protection against Plasmodium berghei.C3d binding to the circumsporozoite protein carboxy-terminus deviates immunity against malaria.Heterologous prime-boost immunization in rhesus macaques by two, optimally spaced particle-mediated epidermal deliveries of Plasmodium falciparum circumsporozoite protein-encoding DNA, followed by intramuscular RTS,S/AS02A.Plasmodium falciparum malaria blood stage parasites preferentially inhibit macrophages with high phagocytic activity.PRKAR1A inactivation leads to increased proliferation and decreased apoptosis in human B lymphocytes.MFG-E8/Lactadherin Promotes Tumor Growth in an Angiogenesis-Dependent Transgenic Mouse Model of Multistage CarcinogenesisVaccine adjuvants: is the pipeline clogged?Combining immunoprofiling with machine learning to assess the effects of adjuvant formulation on human vaccine-induced immunity
P50
Q26865242-C0C9E24D-27CD-42CE-BABC-00456B978D6CQ33481160-A172BB67-E0E5-44BA-BADC-A0C172D0720EQ33757269-CC40697A-8E3C-43D2-854E-F221525E6A6CQ33996076-AF1A6310-20E7-42F4-97CC-9D011EFEC29CQ34373095-6203E02A-88C6-4091-A55F-A7EE020FCFF7Q34703631-9EAFA3E9-60DB-4FC7-ADE5-F85AEED0D144Q34703643-E786481F-BA3F-4114-B3DC-B9F30F4AF65BQ34705057-8A9AD5A7-9766-4ACE-93DD-4BF58CC12332Q35251560-00D8018B-DDF3-4299-9E42-76EB65D89B31Q35551943-9D1D53F4-2A4D-43F4-93FE-53581F9BB71BQ35738697-D16DD2A4-831D-4485-91D2-3F8817DC9C89Q35761670-9B73DB07-21A6-4302-B598-6BFD2189D196Q36420206-560C8F98-8FD8-48FA-9FD9-D0B57E0BAC5CQ36567985-E638516A-0C08-478B-AFD3-0EFA8B8507EAQ37039140-59DD79E5-C848-4891-A128-C68F06ACA66CQ37117761-9CEC066E-88B5-4019-8DFC-4F71EF731E17Q37127370-D106B8A6-91C5-4622-A96D-7E1C44FDC242Q40236751-CD434DAE-21EC-440A-ABC7-3DEB4A460ABCQ40263989-CBF7F63C-9A25-4962-AC13-25F0A0CEB13DQ40356762-4E87405C-FF6A-4DCC-AEF5-06DF56551EF9Q42282048-2F7E39B0-187D-41D8-8654-2949AB2FA271Q42288680-79F444D8-E341-4CC3-B8E6-39816326606EQ44146761-15CE5E1F-49C7-4392-9997-B9F18EB34E6CQ44161140-46D3C181-AE8F-4B40-8130-83AAEF31E2BCQ44423014-A8B6F019-2F6F-4C8A-814C-7593C1E2AA6BQ47831305-76F8EB55-E13B-4E7F-96E5-0D52BD89AC26Q47846079-FDD2AFE4-F8E7-472F-9DF3-545E7FDD8414Q48003719-53C8E51E-6216-457B-900C-9929E8B10886Q48026631-FBC3D7AE-66B1-43F1-9EBD-B71DE7CA4392Q48036524-AB25F0A2-6FA8-4FC2-9617-8A40410F2B44Q52002984-91A82F48-AE98-4BCD-AEE7-A25CEDD26A13Q58429003-C572B425-8503-425E-A377-3E62542B21A5Q84566614-9C43F993-6E99-4E3E-9442-BCE25CD77C1AQ90560580-792382D8-0928-408A-8749-3A16ABE223F2
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Wolfgang W Leitner
@ast
Wolfgang W Leitner
@en
Wolfgang W Leitner
@es
Wolfgang W Leitner
@nl
Wolfgang W Leitner
@sl
type
label
Wolfgang W Leitner
@ast
Wolfgang W Leitner
@en
Wolfgang W Leitner
@es
Wolfgang W Leitner
@nl
Wolfgang W Leitner
@sl
prefLabel
Wolfgang W Leitner
@ast
Wolfgang W Leitner
@en
Wolfgang W Leitner
@es
Wolfgang W Leitner
@nl
Wolfgang W Leitner
@sl
P106
P21
P31
P496
0000-0003-3125-5922